Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells in the tumor microenvironment.

The company is based on findings from the lab of Laurie Glimcher, president and CEO of Dana-Farber Cancer Institute, who is a co-founder of the newco. Glimcher’s studies have focused on the stress response since her tenure at Weill Cornell Medical College. ...